JPMorgan Chase & Co. Sells 1,077,087 Shares of Astrazeneca Plc $AZN

JPMorgan Chase & Co. lowered its position in shares of Astrazeneca Plc (NYSE:AZN) by 22.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,746,985 shares of the company’s stock after selling 1,077,087 shares during the quarter. JPMorgan Chase & Co.’s holdings in Astrazeneca were worth $657,596,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of AZN. Triumph Capital Management bought a new stake in Astrazeneca during the third quarter valued at $25,000. Bangor Savings Bank boosted its position in Astrazeneca by 102.7% during the fourth quarter. Bangor Savings Bank now owns 304 shares of the company’s stock valued at $28,000 after acquiring an additional 154 shares during the last quarter. Eagle Bay Advisors LLC bought a new stake in Astrazeneca during the fourth quarter valued at $30,000. YANKCOM Partnership bought a new position in shares of Astrazeneca during the 4th quarter worth about $31,000. Finally, TFC Financial Management Inc. boosted its position in shares of Astrazeneca by 3,350.0% during the 4th quarter. TFC Financial Management Inc. now owns 345 shares of the company’s stock worth $32,000 after purchasing an additional 335 shares in the last quarter. Institutional investors own 20.35% of the company’s stock.

Astrazeneca Trading Up 1.0%

AZN opened at $183.36 on Wednesday. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.91 and a quick ratio of 0.71. Astrazeneca Plc has a fifty-two week low of $137.23 and a fifty-two week high of $212.71. The firm has a market capitalization of $284.38 billion, a PE ratio of 27.53, a P/E/G ratio of 1.56 and a beta of 0.25. The company’s 50-day moving average is $190.49 and its 200 day moving average is $185.71.

Astrazeneca (NYSE:AZN) last posted its earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share for the quarter, topping analysts’ consensus estimates of $2.52 by $0.06. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. The company had revenue of $15.29 billion for the quarter, compared to analyst estimates of $14.93 billion. As a group, research analysts predict that Astrazeneca Plc will post 9.53 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on AZN. UBS Group reissued a “buy” rating on shares of Astrazeneca in a research report on Friday, April 10th. Jefferies Financial Group reissued a “buy” rating on shares of Astrazeneca in a research report on Tuesday. Weiss Ratings began coverage on shares of Astrazeneca in a research report on Wednesday, March 11th. They set a “buy (b)” rating on the stock. TD Cowen reissued a “buy” rating on shares of Astrazeneca in a research report on Wednesday, March 18th. Finally, Morgan Stanley reissued an “overweight” rating on shares of Astrazeneca in a research report on Wednesday, April 8th. Twelve equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $205.33.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.